EurekaMag.com logo
+ Site Statistics
References:
54,215,046
Abstracts:
30,230,908
PMIDs:
28,215,208
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Prevalence of functional iron deficiency in patients on maintenance hemodialysis treated with recombinant human erythropoietin A single center study



Prevalence of functional iron deficiency in patients on maintenance hemodialysis treated with recombinant human erythropoietin A single center study



International Journal of Artificial Organs 23(8): 576, August




(PDF emailed within 1 workday: $29.90)

Accession: 035548934

Download citation: RISBibTeXText



Related references

Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group. Seminars in Nephrology 10(2 Suppl 1): 11-19, 1990

Diagnosis of functional iron deficiency in hemodialysis patients on maintenance erythropoietin. Journal of the American Society of Nephrology 9(PROGRAM AND ABSTR ISSUE): 213A, Sept, 1998

Iron metabolism under recombinant human erythropoietin therapy in patients on maintenance hemodialysis. International Journal of Artificial Organs 13(2): 109-112, 1990

Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO). Clinical Nephrology 49(1): 45-48, 1998

The effect of treatment with human recombinant erythropoietin on the functional status of patients on maintenance hemodialysis. Terapevticheskii Arkhiv 63(6): 81-86, 1991

Diagnosis and treatment of iron deficiency in patients on maintenance recombinant human erythropoietin. Journal of the American Society of Nephrology 7(9): 1450, 1996

Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3. Renal Failure 27(3): 283-288, 2005

Effect of aluminum on bioavailability of iron in hemodialysis hd patients treated with recombinant human erythropoietin epo. Clinical & Investigative Medicine 12(SUPPL 4): B66, 1989

Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin. Renal Failure 24(2): 245-247, March, 2002

Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis. Casopis Lekaru Ceskych 140(7): 209-213, 2001

Effect of relative hypoparathyroidism on the responsiveness to recombinant human erythropoietin in chronic hemodialysis patients: a single Saudi center experience. Saudi Journal of Kidney Diseases and Transplantation 24(4): 825-831, 2013

Intravenous iron reduces erythropoietin use and improves iron indices in hemodialysis patients with functional iron deficiency. Journal of the American Society of Nephrology 14(Abstracts Issue): 706A, November, 2003

Appropriate intravenous iron maintenance dosage in erythropoietin-treated hemodialysis patients. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 403A-404A, September, 2001

Prevalence of anti-erythropoietin antibodies in ESRD patients on hemodialysis receiving recombinant human erythropoietin. Journal of the American Society of Nephrology 14(Abstracts Issue): 708A, November, 2003

The effect of the treatment with recombinant erythropoietin on the functional status of patients during maintenance hemodialysis. Terapevticheskii Arkhiv 63(6): 81-86, 1991